World

Philippines stops research survey in disputed sea

Jan 26, 2025

Manila [Philippines], January 26: The Philippines says it has suspended a scientific survey in the South China Sea after its fisheries vessels faced "dangerous harassment" and aggressive behaviour from China's coastguard and navy.
The Philippine Coast Guard said on Saturday that three Chinese coastguard vessels and four smaller boats made "aggressive manoeuvres" towards two Philippine Bureau of Fisheries inflatable boats that were on their way to collect sand samples from Sandy Cay near the Philippine-occupied Thitu island on Friday. A Chinese navy helicopter also hovered at an "unsafe altitude" over those craft, it said.
The two countries have been engaging in a long-running series of escalating confrontations in disputed waters of the South China Sea for years. China claims
almost all of the strategic waterway, through which $3 trillion of commerce moves annually, overlapping with claims by the Philippines, Indonesia, Malaysia and Vietnam.
"As a result of this continuous harassment and the disregard for safety exhibited by the Chinese maritime forces", survey operations were suspended, the Philippine Coast Guard said. China Coast Guard said the Philippine vessels had entered waters near Tiexian Reef without permission and attempted to "illegally" land on the reef to collect sand samples.
Source: Ǫatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026